Cargando…

A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease

Background: Five types of HIF-PHIs have been authorized for anemia treatment in CKD patients in China and Japan. These are enarodustat, roxadustat, daprodustat, vadadustat, and molidustat. How effectively they compare to ESAs about clinical results in CKD-DD patients is uncertain. This study examine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jun, Shou, Xinyang, Xu, Yanyan, Jin, Lie, Zhu, Chaoyong, Ye, Xiaolan, Mei, Ziwei, Chen, Peipei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2023
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10085583/ https://www.ncbi.nlm.nih.gov/pubmed/36988549 http://dx.doi.org/10.18632/aging.204611

Ejemplares similares

Hypoxia-inducible factor prolyl hydroxylase inhibitors in kidney transplant recipients
por: Ogata, Masatomo, et al.
Publicado: (2022)

Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor
por: Groenendaal-van de Meent, Dorien, et al.
Publicado: (2020)

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Iron Metabolism
por: Ogawa, Chie, et al.
Publicado: (2023)

Bibliometric analysis of hypoxia inducible factor prolyl hydroxylase inhibitor in anemia
por: Zheng, Li, et al.
Publicado: (2022)

Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia
por: Li, Jing, et al.
Publicado: (2022)

A Novel Prolyl Hydroxylase Inhibitor Protects Against Cell Death After Hypoxia
por: Kontani, Satoru, et al.
Publicado: (2013)

Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications
por: Kim, So Yeon, et al.
Publicado: (2015)

Clinical Potential of Hypoxia Inducible Factors Prolyl Hydroxylase Inhibitors in Treating Nonanemic Diseases
por: Miao, Mengqiu, et al.
Publicado: (2022)

Structure–Activity Relationships and Transcriptomic Analysis of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors
por: Poloznikov, Andrey A., et al.
Publicado: (2022)

Cloning of the Human MORG1 Promoter: Differential Regulation by Hypoxia and Prolyl-Hydroxylase Inhibitors
por: Bondeva, Tzvetanka, et al.
Publicado: (2022)

Pleotropic effects of hypoxia-inducible factor-prolyl hydroxylase domain inhibitors: are they clinically relevant?
por: Chou, Yu-Hsiang, et al.
Publicado: (2023)

Hypoxia inducible factor prolyl hydroxylases in inflammatory bowel disease
por: Lun, Jie, et al.
Publicado: (2023)

Gas tunnel engineering of prolyl hydroxylase reprograms hypoxia signaling in cells
por: Windsor, Peter, et al.
Publicado: (2023)

Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor
por: Kiriakidis, Serafim, et al.
Publicado: (2017)

Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis
por: Chen, Dinghua, et al.
Publicado: (2023)

An updated meta-analysis on the efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor treatment of anemia in nondialysis-dependent chronic kidney disease
por: Zhao, Hanxue, et al.
Publicado: (2023)

Impact of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Renal Function in Patient with Heart Failure
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Impact of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Heart Failure with Preserved Ejection Fraction
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Assessing the Carcinogenicity of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, in Rodents
por: Kowalski, Heather, et al.
Publicado: (2023)

Neuroprotective Effect of HIF Prolyl Hydroxylase Inhibition in an In Vitro Hypoxia Model
por: Savyuk, Maria, et al.
Publicado: (2020)

An Overview of Safety and Efficacy Between Hypoxia-Inducible Factor-Prolyl-Hydroxylase Inhibitors and Erythropoietin-Stimulating Agents in Treating Anemia in Chronic Kidney Disease Patients
por: Sonia, Shamsun Nahar, et al.
Publicado: (2023)

Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China
por: Chen, Nan, et al.
Publicado: (2017)

Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors
por: Locatelli, Francesco, et al.
Publicado: (2022)

The Hypoxia-Inducible Factor Pathway, Prolyl Hydroxylase Domain Protein Inhibitors, and Their Roles in Bone Repair and Regeneration
por: Fan, Lihong, et al.
Publicado: (2014)

Potent and Selective Triazole-Based Inhibitors of the Hypoxia-Inducible Factor Prolyl-Hydroxylases with Activity in the Murine Brain
por: Chan, Mun Chiang, et al.
Publicado: (2015)

Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitors for the Treatment of Anemia in CKD: Additional Pieces of the Jigsaw Puzzle
por: Wish, Jay B.
Publicado: (2021)

Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitor Improves Leukocyte Energy Metabolism in Hereditary Hemorrhagic Telangiectasia
por: Schild, Yves, et al.
Publicado: (2023)

The anaemia treatment journey of CKD patients: from epoetins to hypoxia-inducible factor-prolyl hydroxylase inhibitors
por: Locatelli, Francesco, et al.
Publicado: (2023)

Tuning the Transcriptional Response to Hypoxia by Inhibiting Hypoxia-inducible Factor (HIF) Prolyl and Asparaginyl Hydroxylases
por: Chan, Mun Chiang, et al.
Publicado: (2016)

Safety and Efficacy of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors vs. Erythropoietin-Stimulating Agents in Treating Anemia in Renal Patients (With or Without Dialysis): A Meta-Analysis and Systematic Review
por: Damarlapally, Nanush, et al.
Publicado: (2023)

Microbiota-derived butyrate is an endogenous HIF prolyl hydroxylase inhibitor
por: Wang, Ruth X., et al.
Publicado: (2021)

Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor
por: Groenendaal-van de Meent, Dorien, et al.
Publicado: (2016)

Successful treatment of anti-EPO antibody associated refractory anemia with hypoxia-inducible factor prolyl hydroxylase inhibitor
por: Zhang, Huifang, et al.
Publicado: (2020)

Molecular Characterization and Response of Prolyl Hydroxylase Domain (PHD) Genes to Hypoxia Stress in Hypophthalmichthys molitrix
por: Li, Xiaohui, et al.
Publicado: (2022)

Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors induce autophagy and have a protective effect in an in-vitro ischaemia model
por: Singh, Ayesha, et al.
Publicado: (2020)

Loss of Endothelial Hypoxia Inducible Factor‐Prolyl Hydroxylase 2 Induces Cardiac Hypertrophy and Fibrosis
por: Dai, Zhiyu, et al.
Publicado: (2021)

Comparative effectiveness and acceptability of HIF prolyl-hydroxylase inhibitors versus for anemia patients with chronic kidney disease undergoing dialysis: a systematic review and network meta-analysis
por: Huang, Qiong, et al.
Publicado: (2023)

Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials
por: Yeh, Tzu-Lan, et al.
Publicado: (2017)

Studies on spiro[4.5]decanone prolyl hydroxylase domain inhibitors
por: Holt-Martyn, James P., et al.
Publicado: (2019)

HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons
por: Poloznikov, Andrey A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5bkifj2kdf2lf18658o6oio5i7